Myrbetriq 25 mg contains mirabegron, a prescription medicine for overactive bladder in adults. It belongs to a class called beta-3 adrenergic agonists and works by relaxing the bladder's detrusor muscle during the storage phase, which can reduce sudden urges to urinate, frequent bathroom trips, and urge urinary incontinence.
Myrbetriq 25 mg is an extended-release tablet taken by mouth. Depending on the patient's situation, a healthcare professional may prescribe it alone or together with solifenacin succinate. Overactive bladder causes a sudden, difficult-to-control urge to urinate, often accompanied by frequency and involuntary leakage. Treatment is tailored to the patient's symptoms, history, and how they respond to therapy.
A healthcare professional may prescribe Myrbetriq 25 mg for adult patients with: Urinary urgency Increased urinary frequency Urge urinary incontinence It may also be prescribed alongside solifenacin succinate for select adult patients with overactive bladder.
Mirabegron activates beta-3 adrenergic receptors in the bladder wall. This relaxes the detrusor muscle during urine storage, allowing the bladder to hold urine more effectively and reducing urgency, frequency, and leakage.
The recommended starting dose is 25 mg once daily. After 4 to 8 weeks, a prescriber may increase this to 50 mg once daily based on effectiveness and tolerability. Take exactly as prescribed Swallow the tablet whole with water; do not chew, divide, or crush it Can be taken with or without food Patients with kidney or liver impairment may need dose adjustments or have restrictions on use Do not change the dose or frequency without consulting the prescribing healthcare professional.
Blood pressure: Myrbetriq can raise blood pressure. Monitoring is recommended, particularly for patients with hypertension. The medicine is not recommended for patients with severe uncontrolled hypertension. Urinary retention: Caution is advised for patients with bladder outlet obstruction or those already taking antimuscarinic medicines for overactive bladder, due to the risk of urinary retention. Drug interactions: Mirabegron is a moderate CYP2D6 inhibitor and can affect levels of other medicines processed through that pathway. A prescriber should review all current medications before treatment begins. Allergic reactions: Angioedema, including swelling of the face, lips, tongue, or throat, has been reported. Seek urgent care if any swelling or breathing difficulty develops. Common Side Effects In adult clinical trials, the most commonly reported side effects were: Increased blood pressure Headache Urinary tract infection Nasopharyngitis (cold-like symptoms) Contact a healthcare professional if side effects persist, worsen, or cause concern.
Store as directed on the product packaging. Keep in the original container, away from heat and moisture, and out of reach of children.
It is used to treat overactive bladder in adults, specifically urgency, increased frequency, and urge urinary incontinence.
Mirabegron, a beta-3 adrenergic agonist.
It activates beta-3 receptors in the bladder, relaxing the detrusor muscle so the bladder can store urine more effectively.
25 mg once daily. A prescriber may increase this to 50 mg once daily after 4 to 8 weeks, depending on response and tolerability.
Yes. Periodic blood pressure monitoring is recommended, especially for patients with hypertension.
Yes, in select adult patients, under medical supervision.
Urinary retention is a risk, particularly in patients with bladder outlet obstruction or those taking antimuscarinics. Discuss any relevant symptoms and medicines with a prescriber before starting.
No. Swallow whole with water.